A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab

Paraskevi Fragkou; Maria Souli; Maria Theochari; Christina Kontopoulou; Stelios Loukides; Anna Koumarianou

doi:10.33393/dti.2016.1420

Authors

Paraskevi Fragkou Fourth Department of Internal Medicine, Infectious Diseases Unit, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Maria Souli Fourth Department of Internal Medicine, Infectious Diseases Unit, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Maria Theochari Fourth Department of Internal Medicine, Hematology-Oncology Unit, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Christina Kontopoulou 2nd Radiology Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Stelios Loukides 2nd Respiratory Medicine Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Anna Koumarianou Fourth Department of Internal Medicine, Hematology-Oncology Unit, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

DOI:

https://doi.org/10.33393/dti.2016.1420

Keywords:

OP, organizing pneumonia, pembrolizumab, melanoma, side effect

Abstract

Until recently, chemotherapy for metastatic melanoma had disappointing results. The identification of immune checkpoints such as CTLA-4 and PD-1/PD-L1 has led to the development of an array of monoclonal antibodies (Mabs). These immunologic approaches against tumoral cells come with a novel kind of side effects that the clinician needs to be familiarized with. Herein, we report for the first time a case of organizing pneumonia, based on imaging and cytological analyses of bronchoalveolar lavage, possibly associated with the use of pembrolizumab, an anti-PD-1 Mab recently approved for the treatment of metastatic melanoma.